A Phase 3 interventional study of Lurasidone HCl in Schizophrenia and Schizoaffective Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-12.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 20th largest by enrollment, is one of 2 that started in 2010, is one of 18 in phase 3, and was the 15th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2010.
This study's enrollment of 149 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2010, is one of 21 in phase 3, and was the 16th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
Drug: Lurasidone HCl
40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
Adverse Events
Proportions of subjects with AEs, SAEs, and discontinuations due to AEs.
Time frame: 6 months
Efficacy
Long-term efficacy of lurasidone in subjects with schizophrenia or schizoaffective disorder who have completed Study D1050289
Time frame: 6 months
FPI August 10, 2010-LPV November 28, 2011, locations were private health clinics, university hospitals, private research facilities.
| Milestone | Open Label |
|---|---|
| Started | 149 |
| Completed | 98 |
| Not completed | 51 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Adverse event | 17 |
| Withdrew: Lost to follow-up | 9 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 18 |
| Withdrew: Non-compliance with study drug | 1 |
| Withdrew: Failure to meet eligibility criteria | 1 |
| Withdrew: Administrative | 1 |
Proportions of subjects with AEs, SAEs, and discontinuations due to AEs.
| participants | Lurasidone Overall |
|---|---|
| Any Treatment Emergent Adverse Event | 98 |
| Any Severe Treatment Emergent Adverse Event | 10 |
| Treatment Emergent AE Leading to Discontinuation | 16 |
Long-term efficacy of lurasidone in subjects with schizophrenia or schizoaffective disorder who have completed Study D1050289
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label | — | 8/148 (5.4%) | 47/148 (31.8%) |
| Event | Open Label |
|---|---|
| Schizoaffective DisorderPsychiatric disorders | 3/148 |
| SchizophreniaPsychiatric disorders | 2/148 |
| Suicidal IdeationPsychiatric disorders | 2/148 |
| Bipolar I DisorderPsychiatric disorders | 1/148 |
| Homicidal IdeationPsychiatric disorders | 1/148 |
| ParanoiaPsychiatric disorders | 1/148 |
| Event | Open Label |
|---|---|
| NauseaGastrointestinal disorders | 13/148 |
| InsomniaPsychiatric disorders | 13/148 |
| AkathisiaNervous system disorders | 12/148 |
| AnxietyPsychiatric disorders | 9/148 |
| Age, Categorical(Participants) | Open Label |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 146 |
| >=65 years | 0 |
| Age, Continuous(years) | Open Label |
|---|---|
| Mean | 42.8 ± 11.1 |
| Sex: Female, Male(Participants) | Open Label |
|---|---|
| Female | 55 |
| Male | 93 |
| Region of Enrollment(participants) | Open Label |
|---|---|
| United States | 148 |
The record gives a start of Aug 2010 and a primary completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →